Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Antifungal

Therapeutic area intelligence for Antifungal with 13 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
13
Catalysts
0
Companies
4

Companies

Glenmark Pharmaceuticals →
GSK →
Pfizer →
Sun Pharma Canada →

Assets

Apotex →
Brexafemme →
Ciclopirox →
Fluconazole →
Itraconazole →
Janssen →
Mundipharma →
Voriconazole →

Recent signals(13)

RegulatoryAugust 12, 2026

FDA grants approval status for Voriconazole supplement by Hainan Poly Pharm

The FDA has granted an approval status (AP) for the supplemental application ANDA220043 for Voriconazole submitted by Hainan Poly Pharm.

ClinicalAugust 6, 2026

Study on Fluconazole's Impact on PF-07248144 Pharmacokinetics

The study investigates how fluconazole affects the pharmacokinetics of PF-07248144, including safety and tolerability.

StrategyAugust 3, 2026

FDA Grants Approval for Voriconazole Generic by Zhejiang Novus

The FDA has granted approval for the generic version of Voriconazole under application ANDA220078, submitted by Zhejiang Novus.

RegulatoryAugust 1, 2026

FDA Approval of Ciclopirox Supplement by Sun Pharma Canada

The FDA has approved a supplement for Ciclopirox submitted by Sun Pharma Canada.

RegulatoryJuly 30, 2026

FDA Approves Supplemental Application for Brexafemme (Ibrexafungerp) by GlaxoSmithKline

The FDA has approved a supplemental application for Brexafemme, an antifungal treatment.

RegulatoryJuly 29, 2026

FDA Accepts Supplement for Brexafemme (Ibrexafungerp) by GlaxoSmithKline

The FDA has accepted a supplemental application for Brexafemme, an antifungal treatment.

ClinicalJuly 29, 2026

Pfizer's Study on Itraconazole's Effect on PF-08642534 Pharmacokinetics

Pfizer is conducting a study to evaluate how itraconazole affects the pharmacokinetics of PF-08642534 in healthy adults.

RegulatoryJuly 23, 2026

FDA Accepts Supplement Application for REZZAYO (Rezafungin Acetate)

The FDA has accepted a supplemental application for REZZAYO, an antifungal agent containing Rezafungin Acetate.

RegulatoryJuly 21, 2026

FDA Approves Supplement for Voriconazole by Hainan Poly Pharm

The FDA has approved a supplemental application for Voriconazole submitted by Hainan Poly Pharm.

StrategyJuly 12, 2026

FDA Grants Approval for Voriconazole ANDA220078 by Zhejiang Novus

The FDA has granted an Abbreviated New Drug Application (ANDA) approval for Voriconazole submitted by Zhejiang Novus.

RegulatoryJuly 12, 2026

FDA Accepts Supplement for SPORANOX (Itraconazole) by Janssen

The FDA has accepted a supplemental application for SPORANOX, an antifungal medication containing itraconazole.

StrategyJuly 8, 2026

FDA Accepts ANDA for Posaconazole by Apotex

The FDA has accepted the Abbreviated New Drug Application (ANDA) for Posaconazole submitted by Apotex.

RegulatoryJuly 1, 2026

Glenmark Pharmaceuticals receives FDA acceptance for Ciclopirox ANDA090273

The FDA has accepted Glenmark Pharmaceuticals' Abbreviated New Drug Application (ANDA) for Ciclopirox.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Infectious Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.